The Best SteroidPlotter Alternative in 2026: Why Researchers Are Switching to a Real Pharmacokinetic Engine

If you have spent any time searching for a way to plot compound half-lives or visualise a steroid cycle, you have almost certainly landed on SteroidPlotter. It has occupied a useful niche: paste in a compound, select a half-life value, and get a browser-rendered decay curve. For a rough sketch of elimination timing, it works.

But "rough sketch" is the ceiling. As protocols have grown more complex — multi-compound stacks, peptide co-administration, GLP-1 agonists with weekly injection intervals, longevity cycles with precise trough requirements — the static, web-only architecture of SteroidPlotter has become a structural bottleneck, not a limitation that updates can fix.

This article examines exactly what SteroidPlotter cannot do, what a modern pharmacokinetic intelligence platform requires, and why Halflife was built from the ground up to replace it.

What SteroidPlotter Does — and Where It Stops

SteroidPlotter's core function is monoexponential decay visualisation. Given a compound, a dose, and a half-life constant, it renders a concentration-time curve using the standard first-order elimination formula: C(t) = C₀ · e^{−(ln2/t½)·t}. For single-compound, infrequent-injection protocols, this is interpretable and useful.

The tool's limitations are not cosmetic — they are architectural. They originate in three distinct design decisions that made sense in 2013 but are clinically inadequate for the compound landscape people are using today.

Static Decay Curves With No Accumulation Modeling

SteroidPlotter renders what happens after a single injection. It does not compute what happens when injections recur before full elimination — which is the actual pharmacokinetic reality of every multi-dose protocol. In repeated-dose pharmacokinetics, the relevant metric is not just the decay from a single bolus. It is the accumulation multiplier (R_acc = 1 / (1 − e^{−(ln2/t½)·τ})), which quantifies how far above the single-dose AUC a compound's steady-state concentrations will sit. SteroidPlotter does not compute R_acc. It does not model trough accumulation across injection cycles. It does not tell you when steady-state is reached or what the peak-to-trough ratio will be at plateau.

For testosterone cypionate dosed every seven days — a half-life of approximately 8 days — the accumulation multiplier at steady state is approximately 4.0×. The trough at week 12 is structurally different from the trough after the first injection. SteroidPlotter treats them identically.

No Peptide or GLP-1 Support

SteroidPlotter was built for anabolic steroid esters — long-acting lipophilic compounds with half-lives measured in days. Its mental model, and its compound library, reflects that origin. Short-acting peptides — BPC-157 (t½ ≈ 1.5–4 hours), CJC-1295 no-DAC (t½ ≈ 30 minutes), ipamorelin (t½ ≈ 2 hours), PT-141 (t½ ≈ 3–4 hours) — have pharmacokinetic profiles that behave entirely differently. Trough concentrations drop to near-zero between doses. Frequency of injection is the primary lever on time-above-threshold. SteroidPlotter has no entries for these compounds and no calculation framework suited to their dynamics.

The same gap exists for GLP-1 agonists. Tirzepatide's half-life of approximately 5 days and semaglutide's half-life of approximately 7 days produce steady-state accumulation curves with plateau concentrations that are 2–3× the first-dose peak. For anyone tracking dose escalation timing or evaluating trough coverage between weekly injections, the absence of any accumulation model is a significant analytical blind spot.

No Dynamic Trough Alerts

Protocol adherence depends on knowing when a trough is approaching, not just visualising a curve after the fact. SteroidPlotter generates a static graph. There is no threshold-setting mechanism, no notification layer, and no mechanism to flag when a projected trough falls below a user-defined minimum. The tool is a visualisation utility, not a monitoring system.

Web-Only, No Mobile Interface

SteroidPlotter is a browser-based web tool with no iOS or Android application. Injection logs and concentration monitoring are inherently mobile-use cases — people inject subcutaneously or intramuscularly in contexts where desktop access is not available. The absence of a mobile interface is not a convenience gap; it is a workflow gap. A pharmacokinetic model that cannot be consulted at injection time is a model that will not be consulted consistently.

What a Pharmacokinetic Intelligence Engine Actually Requires

The compounds people are tracking in 2026 span half-lives from 30 minutes (CJC-1295 no-DAC) to 28 days (insulin degludec). They are co-administered in stacks of 3–6 compounds with distinct injection schedules. Trough coverage is the critical parameter — falling below trough threshold on a GH secretagogue stack or a GLP-1 protocol has clinical consequences for the research outcome being tracked.

A platform adequate for this use case must compute across four pharmacokinetic dimensions simultaneously:

• Steady-state accumulation — modeled via the accumulation multiplier R_acc across repeated dosing intervals, not just single-bolus decay
• Peak-to-trough ratio — the ratio C_max/C_trough at steady state, which determines concentration variability over the dosing interval
• Time-to-steady-state — typically 4–5 half-lives; critical for understanding when plateau concentrations are reached in long-acting compounds
• Dynamic trough alerts — real-time notification when projected compound concentration falls below a user-configured threshold

Additionally, a modern compound tracking platform must support the full range of compounds people are actively using — not just steroid esters. That means peptides, GLP-1 agonists, growth hormone secretagogues, longevity compounds, and insulin analogues, each with pharmacokinetic parameters sourced from and linked to peer-reviewed literature.

Halflife vs. SteroidPlotter: Side-by-Side Technical Comparison

The table below evaluates both platforms across the attributes that matter for compound half-life tracking and multi-dose protocol analysis in 2026.

The gap is not a feature count difference. It is an architectural one. SteroidPlotter was designed as a visualisation utility. Halflife was designed as a pharmacokinetic modeling and protocol management platform. They occupy different product categories.

The Halflife Pharmacokinetic Engine: Technical Architecture

Halflife computes pharmacokinetic parameters using validated mathematical models sourced from clinical pharmacology literature. The core calculations that SteroidPlotter does not perform are described below.

Steady-State Accumulation: R_acc Computation

For any compound administered at dose interval τ with half-life t½, the accumulation multiplier at steady state is computed as:

This multiplier defines the ratio of steady-state AUC to single-dose AUC. For a compound like testosterone enanthate (t½ ≈ 4.5 days, τ = 7 days), R_acc ≈ 2.0×. For semaglutide (t½ ≈ 7 days, τ = 7 days), R_acc ≈ 2.0×. For tirzepatide (t½ ≈ 5 days, τ = 7 days), R_acc ≈ 1.7×. Halflife surfaces this as a live value on the compound detail screen.

Peak-to-Trough Ratio at Steady State

The peak-to-trough ratio (PTR) quantifies intra-cycle concentration variability at steady state. A PTR approaching 1.0 indicates near-flat concentration (highly desirable for GLP-1 agonists and longevity compounds). A high PTR indicates large swings between injection and pre-dose trough — clinically significant for protocols targeting consistent receptor occupancy.

For anyone titrating a GH secretagogue stack — CJC-1295 DAC (t½ ≈ 8 days) paired with ipamorelin (t½ ≈ 2 hours, 3× daily dosing) — the PTR profiles of the two compounds are structurally different and interact across different time scales. Halflife models both simultaneously on the protocol overlay screen.

Time-to-Steady-State Estimation

Steady state is conventionally reached at 4–5 elimination half-lives. For a compound like insulin degludec (t½ ≈ 25 hours), steady state arrives in approximately 4–5 days. For testosterone undecanoate (t½ ≈ 21 days), steady state is not reached until week 12–15. Halflife computes this automatically and surfaces it on the protocol timeline — eliminating the common error of adjusting dose before plateau concentrations are established.

Dynamic Trough Alerts

Trough alerts in Halflife are not retroactive notifications. They are predictive: the platform projects forward from the last logged injection using the compound's half-life parameters and fires a push notification when the projected serum concentration crosses the user-set threshold. Alert timing is protocol-specific — a peptide dosed twice daily will produce alerts on a sub-24-hour cadence; testosterone cypionate on a 5–7 day cadence. SteroidPlotter has no analog to this feature.

Compound Support: The Peptide and GLP-1 Gap

The compound landscape people are navigating has expanded dramatically beyond the anabolic ester protocols that tools like SteroidPlotter were designed for. Halflife's compound database covers 45+ entries across six pharmacological classes:

• GLP-1 / GIP receptor agonists — tirzepatide, semaglutide, retatrutide, cagrilintide with full accumulation modeling at weekly dosing intervals
• Growth hormone secretagogues — CJC-1295 DAC and no-DAC, ipamorelin, GHRP-2, GHRP-6, hexarelin, sermorelin, tesamorelin with short-acting t½ modeling
• Recovery and tissue repair peptides — BPC-157, TB-500, PEG-MGF, AOD-9604 with sub-24-hour half-life computation
• Testosterone esters — testosterone cypionate, enanthate, undecanoate with ester-adjusted half-life values per the published literature
• Longevity and cognitive compounds — NAD+ injectable, epitalon, SS-31, MOTS-c, GHK-Cu, selank, semax
• Insulin analogues — rapid-acting, regular, NPH, glargine, detemir, and degludec with sub-type-specific half-life parameters

Every compound profile includes the published half-life range, peak serum timing, mechanism of action summary, standard dosing reference, and a direct link to the sourcing PubMed study. SteroidPlotter's compound library does not include a single entry from the GH secretagogue, peptide, GLP-1, or longevity categories. That is not a gap that can be patched with a feature update — it reflects a fundamentally different scope of intended use.

Mobile-First Protocol Intelligence: Why Platform Matters

Injection logging is a point-of-care activity. Researchers inject subcutaneously in the abdomen, thigh, or deltoid — not seated at a desktop computer. The information they need at injection time — has the previous dose cleared sufficiently? what is the current projected trough? what concentration will this dose stack onto at steady state? — is precisely what SteroidPlotter cannot surface, and could not surface even with a mobile wrapper, because the underlying calculations do not exist.

Halflife's iOS application delivers the full pharmacokinetic engine on the device used at injection time:

• Protocol dashboard — live concentration curve for the full active stack, updating in real time from logged injections
• Trough alert system — configurable threshold per compound, push notification before trough is crossed
• Injection log — persistent dose, volume, concentration, and site records with timeline view
• Reconstitution calculator — BAC water volume calculator, lyophilised peptide concentration converter, syringe unit conversion
• Compound database — 45+ profiles with half-life values, peak timing, and sourced literature references, available offline

Who Needs More Than SteroidPlotter

SteroidPlotter serves one specific use case adequately: someone running a single or small number of long-acting steroid esters who wants a quick visual of the theoretical decay curve for a single injection. Outside that envelope, its limitations are immediately binding.

The following protocol types require the computational capabilities that only a full pharmacokinetic engine provides:

• Peptide protocols — sub-4-hour half-lives require frequency-based accumulation modeling that static single-bolus decay cannot represent
• GLP-1 dose escalation tracking — tirzepatide and semaglutide accumulate to 1.7–2.0× plateau concentrations; understanding when steady state is reached is essential for evaluating dose escalation timing
• GH secretagogue stacks — CJC-1295 DAC (t½ ≈ 8 days) paired with ipamorelin (t½ ≈ 2 hours) produces asymmetric accumulation profiles across time scales that only simultaneous multi-compound modeling can represent
• TRT with peptide co-administration — protocols combining testosterone cypionate with BPC-157 and ipamorelin span half-lives from 2 hours to 8 days; a single graph cannot represent the interaction
• Longevity and epigenetic cycles — compounds like epitalon (cyclical dosing) and MOTS-c require dosing interval modeling that is absent from SteroidPlotter's single-dose framework

Conclusion: A Visualisation Tool vs. a Pharmacokinetic Intelligence Engine

SteroidPlotter occupies a legitimate historical niche. It made compound half-life visualisation accessible when the alternative was manual spreadsheet modeling. In 2026, it remains useful for a specific, narrow use case: simple decay curve sketching for single steroid ester protocols, on desktop, without a need for accumulation modeling, alerts, logging, or peptide support.

For the compound landscape people are actually using — peptides, GLP-1 agonists, secretagogue stacks, TRT protocols, longevity cycles — SteroidPlotter is architecturally incapable of answering the questions that matter: What is my current trough concentration? When does this compound reach steady state? What is my peak-to-trough ratio at plateau? What happens to my projected concentrations if I shift my injection day?

Halflife was built to answer those questions. The platform computes steady-state accumulation, peak-to-trough ratios, and R_acc multipliers across 45+ compounds with citation-backed pharmacokinetic parameters, surfaces dynamic trough alerts on mobile, and maintains a persistent injection log across protocol cycles. That is not a SteroidPlotter with more features. It is a different category of tool.